On July 30, GENFLEET-B fell 5.41% in regular trading to HK$26.32, with turnover of approximately HK$21.70 million, marking the third consecutive trading day of decline.

On the news front, competitor Revolution Medicines' oral RAS inhibitor daraxonrasib has had its New Drug Application accepted by the FDA, based on pivotal Phase III RASolute 302 study data. GENFLEET-B's core product GFH375 is also a KRAS G12D inhibitor, currently conducting a Phase III registrational clinical study targeting second-line and beyond pancreatic cancer. The competitor's advancement into regulatory review continues to pressure the company's best-in-class positioning. Additionally, institutional holder Wellington Management recently made minor reductions in its stake, contributing to weak market sentiment around the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)